Abstract 536P
Background
We aim to evaluate the technical evolution and the long-term outcome of the surgical resection of the pulmonary metastases (PMs) in osteosarcoma.
Methods
We retrospectively reviewed patients with osteosarcoma who underwent pulmonary metastasectomy between Nov. 2002 and Nov. 2022 in our institution. We investigated the surgical techniques, post-metastasectomy overall survival (OS), as well as the clinicopathological factors associated with patients’ survival.
Results
230 cases of surgical resection of PMs were performed over the past 20 years in a total of 141 patients. The M:F ratio was 92:49, with a median age of 17 yro. During the two decades, the pulmonary metastasectomy has been continuously evolving, from the prototype of large- and oligo-metastases with upfront surgery of video-assisted lobectomy, toward the trend of small- and multiple metastases with thoracotomy, video-assisted manual palpation (VAMP) and wedge resection after a pre-operative non-progression disease control (the “Ruijin protocol”). The 3-yr and 5-yr OS of our group were 50.3% and 40.9%, respectively and reached a plateau in the recent years. Univariate analysis demonstrated that >=3 lesions (p<0.001), large-sized PM (p<0.001), CEA (p=0.0516), NSE (p=0.0166) and PLR (p=0.0587) were predictive factors associated with the surgical outcome. Surprisingly, the incidence of detecting extra tiny PMs during surgical exploration has increased from 11% to 55.7% over the two decades, and was found to a novel independent risk factor for the long-term survival(P=0.03). Of note, our premature experience suggested that post-operative early tumor rebound might be drastically reduced in patients treated with tyrosine-kinase inhibitors in the peri-operative setting (p<0.05).
Conclusions
Through the relentless effort of two decades, we have reached a “Ruijin protocol” of pulmonary metastasectomy of osteosarcoma, with a long-term survival of ∼30%. Such survival plateau might be further improved by adding novel biomarkers and therapeutic modalities (e.g. targeted therapy) into the armamentarium against such disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Science Foundation of China, grant No. 82141116; Natural Science Foundation of Shanghai, grant No. 20ZR1434000; Shanghai Municipal Health Commission, grant No. 202140124.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract